Rallybio Faces Critical Juncture Amid Nasdaq Compliance Crisis

While reporting improved quarterly figures, biotechnology firm Rallybio finds itself in a precarious battle for its stock market survival. The company’s financial metrics show signs of stabilization, yet its shares continue to struggle desperately to maintain their listing status.

Financial Performance Shows Modest Improvement

For the second quarter of 2025, Rallybio recorded a net loss of $9.7 million, equivalent to $0.22 per share. This represents a notable improvement compared to the same period last year. The company’s operating loss reached approximately $10.1 million, while research and development expenses declined to $6.1 million, indicating more disciplined cost management practices.

Strategic Portfolio Reshuffling

July 2025 marked a significant strategic pivot for Rallybio when the company divested its interests in the REV102 program to Recursion Pharmaceuticals. The transaction generated an immediate payment of $7.5 million plus potential milestone payments, extending the company’s financial runway through mid-2027.

However, not all development programs have survived the company’s strategic review. Rallybio had already terminated development of RLYB212 in April 2025 after the program failed to meet efficacy targets for preventing fetal and neonatal alloimmune thrombocytopenia.

Should investors sell immediately? Or is it worth buying Rallybio?

All Hopes Pinned on RLYB116

Despite these setbacks, Rallybio continues to advance its RLYB116 program. The company initiated a Phase 1 study in June 2025 to confirm pharmacokinetic and pharmacodynamic properties, with crucial data expected in the third and fourth quarters of 2025. The outcome of this study will likely determine the company’s future trajectory.

Nasdaq Listing Requirements at Risk

The most immediate challenge emerges from the stock market itself. In February 2025, Rallybio received a notification from Nasdaq after its share price fell below the minimum requirement of $1.00. The compliance deadline expired on August 25, 2025.

Recent trading patterns paint a concerning picture: shares closed at $0.537 on Friday, marking a 4.21% decline. This continued a downward trend with three consecutive losing sessions and an 11.16% drop over the past ten trading days. Available evidence suggests Rallybio has missed the Nasdaq compliance deadline, raising serious questions about its listing future.

Critical Factors at a Glance

• Quarterly performance: $9.7 million net loss ($0.22 per share)
• Asset divestment: $7.5 million immediate proceeds from REV102 sale extends cash runway to mid-2027
• Program termination: RLYB212 discontinued in April 2025 due to insufficient efficacy
• Pipeline focus: Pivotal RLYB116 data anticipated in Q3 and Q4 2025
• Listing status: Share price remains well below $1.00, with Nasdaq compliance deadline likely missed

The coming weeks will prove decisive in determining whether Rallybio can preserve its exchange listing or if the company’s financial improvements have arrived too late to avert a delisting crisis.